Evidence map›Paper›PMID 37306526›Full record

ArticleOncotarget2023

LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.

Jianli Zhou, Drew Sturtevant, Cassie Love, Aditya Kulkarni, Neha Biyani, Umesh Kathad, Elizabeth Thacker, Sandeep Dave, Kishor Bhatia

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jianli ZhouLantern Pharma Inc., Plano, TX 75024, USA.
Drew SturtevantLantern Pharma Inc., Plano, TX 75024, USA.
Cassie LoveDepartment of Medicine, Duke University, Durham, NC 27708, USA.
Aditya KulkarniLantern Pharma Inc., Plano, TX 75024, USA.
Neha BiyaniLantern Pharma Inc., Plano, TX 75024, USA.
Umesh KathadLantern Pharma Inc., Plano, TX 75024, USA.
Elizabeth ThackerData Driven Bioscience, Durham, NC 27707, USA.
Sandeep DaveDepartment of Medicine, Duke University, Durham, NC 27708, USA.
Kishor BhatiaLantern Pharma Inc., Plano, TX 75024, USA.
Duke University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advances in therapies treating non-Hodgkin's lymphoma (NHL), 20~40% of patients experience relapsed or refractory disease. While solid tumors with homologous recombination deficiencies have been successfully targeted with synthetic lethal agents such as poly-ADP ribose polymerase (PARP) inhibitors, such synthetic lethality strategy has not yet been approved to treat patients with NHL. Here we investigated the mechanism of action (MoA) and therapeutic potential of a new-generation acylfulvene compound, LP-284, in both

Indexed as

Lymphoma, Non-HodgkinAnimalsBortezomibDNA Breaks, Double-StrandedDNA RepairHumansMiceSesquiterpenesSpiro CompoundsacylfulveneBortezomibSesquiterpenesSpiro CompoundsATMDNA damagehomologous recombination repairnon-Hodgkin's lymphomatranscription-coupled nucleotide excision repair

Identifiers

PMID37306526
PMCPMC10259262
OpenAlexW4380290471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.